General Information of Drug (ID: DMF8Y74)

Drug Name
Hydroxyzine Drug Info
Synonyms
Atara; Atarax; Ataraxoid; Atarazoid; Atarox; Atazina; Aterax; Deinait; Durrax; Hidroxizina; Hychotine; Hydroksyzyny; Hydroxine; Hydroxizine; Hydroxizinum; Hydroxycine; Hydroxyzin; Hydroxyzinum; Hydroxyzyne; Idrossizina; Neurozina; Nevrolaks; Orgatrax; Pamazone; Parenteral; Paxistil; Placidol; Plaxidol; Tranquizine; Traquizine; Vistaril; Atarax base; Hydroksyzyny [Polish]; Hydroxyzine Hcl; Hydroxyzine base; Hydroxyzine hydrochloride; Idrossizina [DCIT]; NP 212; UCB 4492; UCB 492; Atarax (TN); Hidroxizina [INN-Spanish]; Hy-Pam 25; Hydroxyzine (INN); Hydroxyzine [INN:BAN]; Hydroxyzinum [INN-Latin]; Marex (TN); Neo-Calma; Tran-Q; U.CB 4492; Vesparaz-Wirkstoff; Vistaril (TN); U.C.B 4492; N-(4-Chlorobenzhydryl)-N'-(hydroxyethoxyethyl)piperazine; N-(4-Chlorobenzhydryl)-N'-(hydroxyethyloxyethyl)piperazine; Ethanol, 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-(9CI); 1-(p-Chloro-.alpha.-phenylbenzyl)-4-[2-[(2-hydroxyethoxy)ethyl]piperazine; 1-(p-Chloro-alpha-phenylbenzyl)-4-(2-(2-hydroxyethoxy)ethyl)piperazine; 1-(p-Chloro-alpha-phenylbenzyl)-4-(2-hydroxyethoxyethyl)piperazine; 1-(p-Chlorobenzhydryl)-4-(2-(2-hydroxyethoxy)ethyl)diethylenediamine; 1-(p-Chlorobenzhydryl)-4-(2-(2-hydroxyethoxy)ethyl)piperazine; 1-(p-Chlorobenzhydryl)-4-[2-(2-hydroxyethoxy)ethyl]diethylenediamine; 1-(p-Chlorobenzhydryl)-4-[2-(2-hydroxyethoxy)ethyl]piperazine; 1-(p-Chlorodiphenylmethyl)-4-(2-(2-hydroxyethoxy)ethyl)piperazine; 1-(p-Chlorodiphenylmethyl)-4-[2-(2-hydroxyethoxy)ethyl]piperazine; 2-(2-(4-((4-Chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)ethanol; 2-(2-(4-(p-Chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)ethanol; 2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)ethanol; 2-[(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethyl)oxy]ethanol; 2-[2-[4-(p-Chloro-.alpha.-phenylbenzyl)-1-piperazinyl]ethoxy]ethanol; 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]ethanol
Therapeutic ClassHypnotics and Sedatives
Cross-matching ID
PubChem CID
3658
ChEBI ID
CHEMBL896
CAS Number
CAS 68-88-2
TTD Drug ID
D0O6SX
INTEDE Drug ID
DR0840
ACDINA Drug ID
D00318

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name NES FDR q-val Tag % Leading Edge Genes
ECM-receptor interaction 1.75 3.29e-1 80/88 (90.91%) COL6A2;VWF;TNC;...
Starch and sucrose metabolism 1.70 2.54e-1 25/36 (69.44%) PYGB;GAA;GBE1;...
Regulation of lipolysis in adipocytes 1.68 2.06e-1 52/55 (94.55%) PLIN1;FABP4;NPY1R;...
Viral protein interaction with cytokine and cytokine re... 1.66 1.72e-1 84/100 (84%) ACKR3;CXCL6;CXCL14;...
PPAR signaling pathway 1.61 2.21e-1 66/74 (89.19%) PLIN1;ACSL1;ADIPOQ;...
Complement and coagulation cascades 1.59 2.06e-1 76/85 (89.41%) CLU;VWF;F2R;...
Nicotine addiction 1.58 1.91e-1 32/40 (80%) GABRP;GABRE;GRIA2;...
Mineral absorption 1.58 1.68e-1 48/60 (80%) MT1H;MT1HL1;MT1X;...
Systemic lupus erythematosus 1.57 1.69e-1 45/135 (33.33%) C7;C1S;C1R;...
Ether lipid metabolism 1.56 1.70e-1 32/49 (65.31%) PLA2G2A;PAFAH1B1;PLA2G4C;...
Arginine biosynthesis 1.53 2.06e-1 17/22 (77.27%) ASS1;NOS3;ASL
Steroid biosynthesis 1.51 2.15e-1 19/20 (95%) DHCR24;NSDHL;TM7SF2;...
Staphylococcus aureus infection 1.49 2.54e-1 72/95 (75.79%) KRT23;KRT17;KRT14;...
Cocaine addiction 1.48 2.60e-1 42/49 (85.71%) CREB5;MAOA;PRKACB;...
Malaria 1.48 2.43e-1 44/50 (88%) THBS1;ACKR1;CCL2;...
Glycerophospholipid metabolism 1.46 2.62e-1 71/98 (72.45%) PNPLA6;PLA2G2A;PLA2G4C;...
AGE-RAGE signaling pathway in diabetic complications 1.46 2.52e-1 97/100 (97%) NOS3;CCL2;MMP2;...
Cytokine-cytokine receptor interaction 1.42 3.29e-1 246/295 (83.39%) ACKR3;CXCL6;CXCL14;...
Neuroactive ligand-receptor interaction 1.39 3.77e-1 294/341 (86.22%) NTS;F2R;GABRP;...
Fatty acid biosynthesis 1.38 3.96e-1 16/18 (88.89%) ACSL1;FASN;ACSL4;...
Estrogen signaling pathway 1.35 4.43e-1 119/137 (86.86%) KRT23;KRT17;NOS3;...
Neomycin, kanamycin and gentamicin biosynthesis 1.34 4.49e-1 5/5 (100%) HK2;HK3;HK1
Olfactory transduction 1.34 4.42e-1 69/440 (15.68%) NCALD;PRKACB;CALML5;...
Glycine, serine and threonine metabolism 1.33 4.57e-1 31/40 (77.5%) GLDC;MAOA;MAOB;...
Cell adhesion molecules 1.32 4.49e-1 118/148 (79.73%) SDC2;CLDN5;ICAM2;...
Focal adhesion 1.30 5.04e-1 180/201 (89.55%) COL6A2;VWF;TNC;...
Apelin signaling pathway 1.28 5.40e-1 117/137 (85.4%) CCN2;PLIN1;NOS3;...
Phagosome 1.26 5.77e-1 118/152 (77.63%) CORO1A;THBS1;C1R;...
Relaxin signaling pathway 1.26 5.76e-1 114/129 (88.37%) NOS3;MMP2;COL1A1;...
Pertussis 1.23 5.83e-1 64/76 (84.21%) CXCL6;C1S;C1R;...
MAPK signaling pathway -1.19 8.30e-1 272/294 (92.52%) PRKCB;DDIT3;MAPKAPK3;...
Spliceosome -1.19 8.38e-1 101/150 (67.33%) BUD31;SNU13;LSM7;...
One carbon pool by folate -1.20 8.54e-1 15/20 (75%) FTCD;AMT;GART;...
Nitrogen metabolism -1.21 8.52e-1 16/17 (94.12%) CA9;CA12;CA2
Primary immunodeficiency -1.23 8.55e-1 33/38 (86.84%) IL2RG;DCLRE1C;RFX5;...
Legionellosis -1.24 8.48e-1 51/57 (89.47%) HSPA1L;CASP8;BNIP3;...
Pentose and glucuronate interconversions -1.25 8.27e-1 17/34 (50%) AKR1B1;UGDH;AKR1B10
Arachidonic acid metabolism -1.27 7.83e-1 48/61 (78.69%) PLA2G4A;PLA2G12A;EPHX2;...
Rap1 signaling pathway -1.27 8.07e-1 184/210 (87.62%) MAGI1;KDR;FGFR3;...
Oocyte meiosis -1.27 8.25e-1 90/129 (69.77%) CPEB3;ITPR2;IGF1R;...
VEGF signaling pathway -1.28 8.01e-1 50/59 (84.75%) BAD;PTK2;PRKCB;...
Protein processing in endoplasmic reticulum -1.29 8.38e-1 127/171 (74.27%) EDEM3;SEC13;SEC23A;...
Purine metabolism -1.30 7.92e-1 102/129 (79.07%) NUDT9;ADCY9;PAPSS1;...
Homologous recombination -1.32 7.41e-1 35/41 (85.37%) PALB2;RPA1;RAD50;...
Ovarian steroidogenesis -1.33 7.28e-1 41/51 (80.39%) PLA2G4A;ADCY7;LDLR;...
Fructose and mannose metabolism -1.36 6.60e-1 30/33 (90.91%) ALDOB;TKFC;ALDOC;...
Primary bile acid biosynthesis -1.36 7.04e-1 15/17 (88.24%) AKR1C4;SLC27A5;CYP39A1;...
Protein export -1.39 6.38e-1 17/23 (73.91%) SEC62;SPCS3;SRP14;...
D-Glutamine and D-glutamate metabolism -1.43 5.08e-1 5/5 (100%) GLS2;GLS;DGLUCY
RNA degradation -1.44 5.13e-1 53/79 (67.09%) LSM7;TENT4A;PFKP;...
Steroid hormone biosynthesis -1.46 4.57e-1 43/61 (70.49%) CYP3A4;SRD5A3;AKR1C4;...
Non-homologous end-joining -1.47 4.62e-1 11/13 (84.62%) RAD50;MRE11;LIG4;...
Th17 cell differentiation -1.50 3.94e-1 95/107 (88.79%) NFKBIA;STAT6;IL27RA;...
beta-Alanine metabolism -1.51 4.32e-1 25/30 (83.33%) ACOX1;ALDH9A1;MLYCD;...
Gap junction -1.52 4.77e-1 72/88 (81.82%) PRKCB;PDGFRA;ADCY7;...
Folate biosynthesis -1.56 3.53e-1 23/26 (88.46%) GPHN;DHFR;MOCS2;...
Th1 and Th2 cell differentiation -1.59 3.49e-1 80/92 (86.96%) NFKBIA;STAT6;CD3G;...
Mucin type O-glycan biosynthesis -1.64 2.54e-1 20/36 (55.56%) B4GALT5;GALNT14;GCNT3;...
Antigen processing and presentation -1.72 2.26e-1 60/78 (76.92%) KLRC3;CANX;CIITA;...
Toxoplasmosis -1.83 1.41e-1 103/112 (91.96%) GNAI1;HLA-DOB;JAK2;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 24H